PHARMABLOCK SCIENCES (NANJING), INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.89 CNY | -1.94% |
|
-5.73% | -16.25% |
| Apr. 24 | PharmaBlock Proposes Final Dividend for 2023 | CI |
| Apr. 23 | PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on PharmaBlock Sciences (Nanjing), Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.87% | - |
PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Extraordinary Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
32.89
CNY
Average target price
40
CNY
Spread / Average Target
+21.62%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.25% | 924M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 300725 Stock
- Funds and ETFs PharmaBlock Sciences (Nanjing), Inc.
